HNL Lab Medicine announces groundbreaking digital pathology investment

HNL Lab Medicine, a leading multi-regional US-based clinical diagnostics laboratory, has made a groundbreaking investment in digital pathology, having selected solutions from Proscia, a digital pathology software company, and Leica Biosystems, a manufacturer of high-quality imaging hardware, to establish an advanced digital pathology practice.

This investment will enhance the laboratory’s diagnostic capabilities, improve efficiency, and ultimately provide better patient care. The initiative combines Proscia’s innovative digital pathology software platform Concentriq Dx and Leica Biosystems’ scanner hardware. Proscia’s Concentriq Dx drives routine workflows, streamlines collaboration and is designed for realising the promise of pathology’s AI-powered future. Combined with Leica Biosystems’ innovative high throughput scanner hardware, this solution will enable HNL Lab Medicine’s pathologists to get to the correct diagnosis more efficiently, benefiting both patients and healthcare providers.

“We are excited to embark on this digital pathology journey with Proscia and Leica Biosystems. We chose Leica Biosystems as our whole slide imaging vendor due to their high image quality and demonstrated ability to handle large volumes. We selected Proscia’s Concentriq Dx as our digital pathology platform because it aligns with HNL Lab Medicine’s vision for innovation and efficiency. These two companies will allow us to transform into a digital practice, enabling HNL Lab Medicine to deliver on the promise of precision medicine to improve patient care,” said Dr Jordan Olson, Medical Director of HNL Lab Medicine.

The substantial investment in digital pathology is part of HNL Lab Medicine’s ongoing commitment to harnessing advanced technologies to improve patient outcomes. By embracing digital innovation initiatives like digital pathology, HNL Lab Medicine aims to provide superior diagnostic services. For more information, visit hnl.com.


Latest Issues